SSA
RVLP

Schonfeld Strategic Advisors’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-151,400
Closed -$819K – 1957
2020
Q3 		$819K Buy
+151,400
New +$872K 0.02% 755

Other funds holding RVLP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Schonfeld Strategic Advisors's RVLP Position: Q4 2020 in Review

Schonfeld Strategic Advisors sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2020, closing a stake of 151,400 shares — an estimated $819K sold.

Schonfeld Strategic Advisors first reported a position in RVLP in Q3 2020 and held it in 1 quarter. The position peaked at $819K in Q3 2020. 60 funds tracked by Wall St. Rank hold RVLP as of Q4 2020.

  • Schonfeld Strategic Advisors reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2020 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 151,400 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2020, an estimated $819K.
  • Schonfeld Strategic Advisors first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q3 2020 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's RVL Pharmaceuticals plc Ordinary Shares position peaked at $819K in Q3 2020.
  • 60 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.